{"id":508651,"date":"2021-07-01T06:33:12","date_gmt":"2021-07-01T10:33:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/"},"modified":"2021-07-01T06:33:12","modified_gmt":"2021-07-01T10:33:12","slug":"alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/","title":{"rendered":"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease"},"content":{"rendered":"<p>        <!--.bwlistdecimal { list-style-type: decimal }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease<\/b><\/p>\n<p>TAMPA, Fla.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alzamend.com&amp;esheet=52453471&amp;newsitemid=20210701005395&amp;lan=en-US&amp;anchor=Alzamend+Neuro&amp;index=1&amp;md5=3940841ee161adf8b971aafb72425621\">Alzamend Neuro<\/a>\u00ae, Inc. (Nasdaq: ALZN) (\u201c<b>Alzamend<\/b>\u201d), a preclinical stage biopharmaceutical company, today announced that it submitted an investigational new drug (\u201cIND\u201d) application to the U.S. Food and Drug Administration (\u201cFDA\u201d) for the initiation of a Phase 1 clinical study of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Falzamend.com%2Fpipeline%2F&amp;esheet=52453471&amp;newsitemid=20210701005395&amp;lan=en-US&amp;anchor=AL001&amp;index=2&amp;md5=3c5ec5d1ac9b6dcbc885d7f1cac5a2f6\">AL001<\/a> on June 30, 2021. The Phase 1, first-in-human study is for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer\u2019s disease.\n<\/p>\n<p>\nFollowing completion of this initial study, Alzamend intends to initiate a Phase 1\/2a clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AL001 in Alzheimer\u2019s disease patients. Presuming favorable data, a subsequent Phase 2b program is planned to target appropriate doses for the pivotal Phase 3 safety\/efficacy clinical program required for regulatory approval.\n<\/p>\n<p>\n\u201cThis IND submission represents a key milestone for Alzamend as we continue to advance our proprietary pipeline. We believe AL001 could potentially provide clinicians with a major improvement over current lithium-based treatments and may constitute a means of treating Alzheimer\u2019s disease and other neurodegenerative diseases and psychiatric disorders. We look forward to providing more details on the timeline and market opportunity following FDA clearance of the IND, if obtained,\u201d commented <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Falzamend.com%2Fabout%2F&amp;esheet=52453471&amp;newsitemid=20210701005395&amp;lan=en-US&amp;anchor=Stephan+Jackman%2C+Chief+Executive+Officer&amp;index=3&amp;md5=1d4511b358e14895eeb4fe072bd1529a\">Stephan Jackman, Chief Executive Officer<\/a> of Alzamend.\n<\/p>\n<p>\nBased on preclinical data, AL001 treatment prevents cognitive deficits, depression, and irritability in APPSWE\/PS1dE9 mice, and has shown an improvement of associative learning and memory and irritability compared with lithium carbonate treatments, supporting the potential of this lithium formulation for the treatment of Alzheimer\u2019s disease and psychiatric disorders. Lithium has been marketed for more than 35 years and human toxicology regarding lithium use has been well characterized, potentially allowing Alzamend to rely upon this existing data, potentially reducing the regulatory burden for safety data.\n<\/p>\n<p>\nAlzamend\u2019s mission is to help the Alzheimer\u2019s disease community by supporting the full product development life cycle of treatment and cures for dementia and Alzheimer\u2019s disease driven by the belief that strong support of research is the foundation for true innovation. Dementia is not a normal part of aging, and there are numerous symptoms that can indicate cognitive and neurological impairments. Alzheimer\u2019s disease is the most common form of dementia. This disease robs people of their loved ones, as memories are erased and personalities are diminished. Alzamend\u2019s vision statement nicely sums up their mission: <strong><i>\u201cTogether We Can \u2018Make Alzheimer\u2019s Just a Memory!\u2019\u2122\u201d.<\/i><\/strong><\/p>\n<p>\nThe economic impact of Alzheimer\u2019s disease can be as devastating as the emotional stress. Over 47 million people in the world currently live with Alzheimer\u2019s disease or dementia, with over 6.2 million in the U.S. (two-thirds are women). The lifetime cost of care for an Alzheimer\u2019s disease patient is estimated at $374,000 in the U.S. According to the Alzheimer\u2019s Association, it is estimated that Alzheimer\u2019s and dementia deaths increased more than 16% in 2021 due to COVID-19. In 2021, Alzheimer\u2019s and dementia will cost the U.S. an estimated $355 billion with the costs expected to rise into the trillions in the next 25 years. In, addition, Medicare and Medicaid is expected to pay approximately $239 billion, or 67% of the treatment and long-term care costs associated with Alzheimer\u2019s disease and dementia, with another $79 billion of out-of-pocket costs. According to the Alzheimer\u2019s Association, eleven million Americans provide an estimated 15.3 billion hours of unpaid care per year, valued at $257 billion, for these patients with two-thirds of these being women, and one-third being daughters.\n<\/p>\n<p><b>About Alzamend Neuro<\/b><\/p>\n<p>\nWe are a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer\u2019s disease. With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Our current pipeline consists of two novel therapeutic drug candidates, AL001 &#8211; a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 &#8211; a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient\u2019s immunological system to combat Alzheimer\u2019s disease. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p><i>This press release contains &#8220;forward looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;projects,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;opportunity,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;potential,&#8221; or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend\u2019s business and financial results are included in Alzamend\u2019s filings with the U.S. Securities and Exchange Commission. All filings are available at <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52453471&amp;newsitemid=20210701005395&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=3b6e2cc5dc8d78661f3cdade6a798963\">www.sec.gov<\/a><i> and on Alzamend\u2019s website at <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.AlzamendNeuro.com&amp;esheet=52453471&amp;newsitemid=20210701005395&amp;lan=en-US&amp;anchor=www.AlzamendNeuro.com&amp;index=5&amp;md5=ef16b66f0300bfd78d7f31a3200913be\">www.AlzamendNeuro.com<\/a><i>.<\/i><\/p>\n<p><b>References:<\/b><\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nAlzheimer\u2019s Association. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alz.org%2Falzheimers-dementia%2Ffacts-figures.%2520&amp;esheet=52453471&amp;newsitemid=20210701005395&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.alz.org%2Falzheimers-dementia%2Ffacts-figures.&amp;index=6&amp;md5=1cfe803f0d2dda0d23a3f247256eb8b8\">https:\/\/www.alz.org\/alzheimers-dementia\/facts-figures.<\/a> . Accessed June 22, 2021.\n<\/li>\n<li>\nStandard of Care: A Repository of Knowledge in the Field of Medicine. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fstandardofcare.com%2Fshowarticle.php%3Fartid%3D1231&amp;esheet=52453471&amp;newsitemid=20210701005395&amp;lan=en-US&amp;anchor=https%3A%2F%2Fstandardofcare.com%2Fshowarticle.php%3Fartid%3D1231&amp;index=7&amp;md5=e7cea5322d7220e8d5898acd4bb4841d\">https:\/\/standardofcare.com\/showarticle.php?artid=1231<\/a>. Accessed June 22, 2021.\n<\/li>\n<\/ol>\n<p>\n\u00a0\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210701005395\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210701005395\/en\/<\/a><\/span><\/p>\n<p>\nEmail: <a rel=\"nofollow\" href=\"mailto:Info@Alzamend.com\">Info@Alzamend.com<\/a> or call: 1-844-722-6333\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America Florida<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> FDA Pharmaceutical Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210701005395\/en\/835633\/3\/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease TAMPA, Fla.&#8211;(BUSINESS WIRE)&#8211;Alzamend Neuro\u00ae, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d), a preclinical stage biopharmaceutical company, today announced that it submitted an investigational new drug (\u201cIND\u201d) application to the U.S. Food and Drug Administration (\u201cFDA\u201d) for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021. The Phase 1, first-in-human study is for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer\u2019s disease. Following completion of this initial study, Alzamend intends to initiate a Phase 1\/2a clinical trial &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-508651","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease TAMPA, Fla.&#8211;(BUSINESS WIRE)&#8211;Alzamend Neuro\u00ae, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d), a preclinical stage biopharmaceutical company, today announced that it submitted an investigational new drug (\u201cIND\u201d) application to the U.S. Food and Drug Administration (\u201cFDA\u201d) for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021. The Phase 1, first-in-human study is for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer\u2019s disease. Following completion of this initial study, Alzamend intends to initiate a Phase 1\/2a clinical trial &hellip; Continue reading &quot;Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T10:33:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease\",\"datePublished\":\"2021-07-01T10:33:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/\"},\"wordCount\":1023,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/\",\"name\":\"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-01T10:33:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk","og_description":"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease TAMPA, Fla.&#8211;(BUSINESS WIRE)&#8211;Alzamend Neuro\u00ae, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d), a preclinical stage biopharmaceutical company, today announced that it submitted an investigational new drug (\u201cIND\u201d) application to the U.S. Food and Drug Administration (\u201cFDA\u201d) for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021. The Phase 1, first-in-human study is for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer\u2019s disease. Following completion of this initial study, Alzamend intends to initiate a Phase 1\/2a clinical trial &hellip; Continue reading \"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-01T10:33:12+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease","datePublished":"2021-07-01T10:33:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/"},"wordCount":1023,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/","name":"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-01T10:33:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210701005395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-submits-ind-application-for-al001-for-dementia-related-to-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=508651"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508651\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=508651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=508651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=508651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}